Roadshow
aetherAI Hema
In collaboration with the National Taiwan University Hospital (NTUH), Bone Marrow Smear Differential Count - aetherAI Hema has received EU CE mark and approval from the Taiwan Food and Drug Administration (TFDA), Ministry of Health and Welfare to commercialize this AI diagnostic tool. This is the first approval case for automatic differential counting on bone marrow smears.
Trained on the world’s largest dataset of over 1 million carefully curated cells, aetherAI Hema is able to perform consistently, with a high average accuracy of 94 percent. Each cell will be classified into one of 15 main categories. Results are readily available with just a few clicks. The verified results can be saved in the system and further used for educational purposes or collaborations between medical technicians and hematologists.
Advanced Medical Imaging with AI
aetherAI takes a two-pronged approach to develop solutions, using our expertise to contribute to the AI revolution. By elevating the standards of medical diagnosis and improving quality of care, we can realize the ultimate value of digital medical imaging.
aetherAI product portfolio development is based on the following two-pronged approach:
Making Whole-Slide Image Solutions standard for routine pathology for seamless integration of AI into workflow.
Using AI-Microscope to conduct medical examinations requiring laborious manual maneuvering and high-resolution imaging, accelerating such processes by only capturing the images necessary for diagnosis.
AI - Powered Pathology Image Management System
By increasing efficiency and easily monitoring workload and process, aetherAI’s offerings help pathologists focus on the most important tasks. The AI-landing environment we provide supports productivity tools for AI training and seamlessly integrates with AI apps, whether aetherAI or 3rd-party.
- Established 2015
- Company aetherAI
- Telephone +886-2-2785-6892
- Address 15F & 15F-1, No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist., Taipei, Taiwan
Advocating AI - driven Digital Pathology
aetherAI’s mission is to use state-of-the-art information technology to improve standards of healthcare and quality of human life.
Milestones
2022
- Has completed A+ round funding of 150 million NTD from Ono Digital Health Investment LLC, Quanta Computer, TBB Venture Capital, and Taimage Investment.
- aetherAI Hema won 3 awards: Taipei Biotech Award Gold Medal, PTRD Gold, and Taiwan Excellence Award.
- aetherAI Endo, Colorectal Polyp and Adenoma Detection has been approved by TFDA in July 2022.
- Expanding the global market. Major achievements: collaborated projects in Japan, and deployment for the University Hospital Tübingen in digital pathology and AI applications.
- Has become one of the partners of EMPAIA, Eco-system for Pathology Diagnostic with AI Assistance.
- Teamed up with Cathay Financial Holdings in medical underwriting AI and won 2022 FinTech Taipei Award.
- aetherAI Joe Yeh won the 2022 Best Bio Startup CEO Award.
2021
- Taiwan government rolls out Asia Silicon Valley Department Plan 2.0 (2021–2024) to expand AIoT applications, which is expected to encourage a digital transformation in healthcare.
- Introduced Real-time Automatic Detection of Colorectal Polyp aetherAI Endo, and Lung Nodule Detection with Low-Dowse CT aetherAI LTDC.
- aetherAI’s annotation-free whole-slide training approach published with global recognition in leading journal Nature Communications.
- Partnership with Novartis Taiwan and Linkou CGMH to use AI to improve diagnosis of blood disease.
2020
- Revenues triple for third year in a row, expanding into global markets.
- TAIPEI Prominent Enterprise Award—R&D Award, Judge’s Award.
- mplementations of digital pathology for National Taiwan University Hospital, Taiwan’s top medical centers, and CGMH Group, Taiwan’s largest private hospital group. The latter is the largest digital pathology project in Taiwan.
- Series A from Quanta Computer.
- Introduction of world’s first fully automated AI system for bone marrow differentials.
- The government’s Six Core Strategic Industries Program is created to transform Taiwan’s biotech and medical technology. The inclusion of information and digital technology is expected to boost smart healthcare development.